SPC Logo


Last Updated on eMC 12-Nov-2013 View changes  | Merck Sharp & Dohme Limited Contact details

1. Name of the medicinal product


2. Qualitative and quantitative composition

Desogestrel B.P.

150 micrograms

Ethinylestradiol Ph.Eur

30 micrograms

3. Pharmaceutical form


4. Clinical particulars
4.1 Therapeutic indications

Oral contraception

4.2 Posology and method of administration

4.2.1 How to take Marvelon

Tablets must be taken in the order directed on the package every day at about the same time with some liquid as needed. One tablet is to be taken daily for 21 consecutive days. Each subsequent pack is started after a 7-day tablet-free interval, during which time a withdrawal bleed usually occurs. This usually starts on day 2-3 after the last tablet and may not have finished before the next pack is started.

4.2.2 How to start Marvelon

No preceding hormonal contraceptive use [in the past month]

It is preferable that tablet intake from the first pack is started on the first day of menstruation in which case no extra contraceptive precautions are necessary.

If menstruation has already begun, (that is 2, 3, or 4 days previously), tablet taking should commence on day 5 of the menstrual period. In this case additional contraceptive precautions must be taken for the first 7 days of tablet taking.

If menstruation began more than 5 days previously then the patient should be advised to wait until her next menstrual period before starting to take Marvelon.

Changing from a 21 day pill or another 22 day pill to Marvelon:

All tablets in the old pack should be finished. The first Marvelon tablet is taken the next day i.e. no gap is left between taking tablets nor does the patient need to wait for her period to begin. Tablets should be taken as instructed in 'How to take Marvelon'. Additional contraceptive precautions are not required. The patient will not have a period until the end of the first Marvelon pack, but this is not harmful, nor does it matter if she experiences some bleeding on tablet-taking days.

Changing from a combined Every Day Pill (28 day tablets) to Marvelon:

Marvelon should be started after taking the last active tablet from the 'Every Day Pill' pack (i.e. after taking 21 or 22 tablets). The first Marvelon tablet is taken the next day i.e. no gap is left between taking tablets nor does the patient need to wait for her period to begin. One tablet is taken daily at the same time, without interruption for 21 days, followed by a 7 day tablet-free period. Each subsequent pack is started after the 7 day tablet-free period has elapsed. Additional contraceptive precautions are not required. Remaining tablets from the Every Day (ED) pack should be discarded. The patient will not have a period until the end of the first Marvelon pack, but this is not harmful, nor does it matter if she experiences some bleeding on tablet-taking days.

Changing from a Progestogen -only Pill (POP or Mini Pill ) to Marvelon:

The first Marvelon tablet should be taken on the first day of the period, even if the patient has already taken a mini pill on that day. One tablet is taken daily at the same time, without interruption for 21 days, followed by a 7 day tablet-free period. Each subsequent pack is started after the 7 day tablet-free period has elapsed. Additional contraceptive precautions are not then required. All the remaining Progestogen-only pills in the mini pill pack should be discarded.

If the patient is taking a (mini) pill, then she may not always have a period, especially when she is breast feeding. The first Marvelon tablet should be taken on the day after stopping the mini pill. All remaining pills in the mini pill packet must be discarded. Additional contraceptive precautions must be taken for the first seven days.

Changing from a progestogen-only injection, implant or from a progestogen- releasing intrauterine system [IUS]

The woman may switch any day from an implant (or the IUS on the day of its removal, from an injectable when the next injection would be due). Additional contraceptive precautions must be taken for the first seven days.

Post-Partum Administration

Following childbirth oral contraceptive administration to non-breast feeding mothers should be started 21 days post-partum in which case no additional contraceptive precautions are required. If intercourse has taken place post-partum, oral contraceptive use should be delayed until the first day of the menstrual period.

If post-partum administration of Marvelon begins more than 21 days after delivery then additional contraceptive precautions are required for the first 7 days.

N.B. Mothers who are breast feeding should be advised not to use the combined pill since this may reduce the amount of breast-milk, but may be advised instead to use a progestogen-only pill (POP).

After miscarriage or abortion administration should start immediately in which case no additional contraceptive precautions are required.

Additional contraceptive precautions

When additional contraceptive precautions are required the patient should be advised either not to have sex, or to use a cap plus spermicide, or for her partner to use a condom.

Rhythm methods should not be advised as the pill disrupts the usual cyclical changes associated with the natural menstrual cycle e.g. changes in temperature and cervical mucus.

How to skip a period

To skip a period, a new pack of Marvelon should be started on the day after finishing the current pack (the patient skips the tablet-free days). Tablet-taking should be continued in the usual way. During the use of the second pack she may experience slight spotting or breakthrough bleeding but contraceptive protection will not be diminished provided there are no tablet omissions. The next pack of Marvelon is started after the usual 7 tablet-free days, regardless of whether the period has completely finished or not.

4.2.3 Management of missed tablets

Advice in case of missed pills

The reliability of Marvelon may be reduced if tablets are forgotten:

If the forgotten tablet is taken within 12 hours, no further precautions are necessary, further tablets should be taken at the usual time.

If one or more tablets are forgotten for more than 12 hours, contraceptive protection will be reduced. The patient should take the last forgotten tablet, even if this means taking two tablets in one day, and then continue to take tablets at the normal time. Additional contraceptive precautions should be taken for the next seven days, and the patient should follow 'the 7-day rule'.

The 7-Day rule

If any one tablet is forgotten for more than 12 hours

If the patient has vomiting or diarrhoea for more than 12 hours

If the patient is taking any of the drugs listed under 'Interactions':

The patient should continue to take her tablets as usual and

Additional contraceptive precautions must be taken for the next 7 days

But - if these 7 days run beyond the end of the current pack, the next pack must be started as soon as the current one is finished, i.e. no gap should be left between packs. (This prevents an extended break in tablet taking which may increase the risk of the ovaries releasing an egg and thus reducing contraceptive protection). The patient will not have a period until the end of 2 packs but this is not harmful nor does it matter if she experiences some bleeding on tablet taking days.

Advice in case of Vomiting or severe diarrhoea

In case of severe gastro-intestinal disturbance, absorption may not be complete and additional contraceptive measures should be taken. Unless diarrhoea is extremely severe, it does not affect steroidal absorption.

If vomiting occurs within 3-4 hours after tablet taking, or in cases of severe or prolonged diarrhoea, the advice concerning missed tablets, as given in Section 4.2.3, is applicable. If the woman does not want to change her normal tablet-taking schedule, she has to take the extra tablet(s) needed from another pack.

4.3 Contraindications

Moderate to severe hypertension

Presence or history of arterial thrombosis (myocardial infarction, cerebrovascular accident) or prodromal conditions (e.g. transient ischaemic attack, angina pectoris).

In addition the presence of more than one of the risk factors for arterial disease (See 4.4 Special warnings and special precautions for use; The Pill and Thrombosis)

Presence or history of venous thrombosis (deep venous thrombosis, pulmonary embolism).

Migraine with focal neurological symptoms

Diabetes mellitus with vascular involvement

Systemic lupus erythematosus or a history of this condition.

Presence or history of severe hepatic disease as long as liver function values have not returned to normal

Presence or history of liver tumours (benign or malignant)

Known or suspected estrogen-dependent tumours, (See 4.4 Special warnings and special precautions for use: The Pill and Cancer); undiagnosed vaginal bleeding

Hypersensitivity to the active substances or to any of the excipients.

4.4 Special warnings and precautions for use

4.4.1 Medical Examination/consultation

Assessment of women prior to starting oral contraceptives (and at regular intervals thereafter) should include a personal and family medical history of each woman. Physical examination should be guided by this and by the contraindications (section 4.3) and warnings (section 4.4) for this product. The frequency and nature of these assessments should be based upon relevant guidelines and should be adapted to the individual woman, but should include measurement of blood pressure and, if judged appropriate by the clinician, breast, abdominal and pelvic examination including cervical cytology.

Women should be advised that oral contraceptives do not protect against HIV infections (AIDS) and other sexually transmissible infections. If there is risk of STI/HIV (including during pregnancy or postpartum), the correct and consistent use of condoms is recommended, either alone or with another contraceptive method.

4.4.2 Warnings

If any of the conditions/risk factors mentioned below is present, the benefits of COC use should be weighed against the possible risks for each individual woman and discussed with the woman before she decides to start using it. In the event of aggravation, exacerbation or first appearance of any of these conditions or risk factors, the woman should contact her physician. The physician should then decide on whether COC use should be discontinued.

Relative Contraindications

Disorders of coagulation.

Other conditions associated with an increased risk of circulatory disease such as latent or overt cardiac failure, renal dysfunction, or a history of these conditions.

Migraine or a history of this condition.

Diabetes mellitus.

Severe depression or a history of this condition.

If the results of liver function tests become abnormal, use should be discontinued.

1. Circulatory Disorders

• Some epidemiological studies have suggested an association between the use of COCs and an increased risk of arterial and venous thrombotic and thromboembolic diseases such as myocardial infarction, stroke, deep venous thrombosis, and pulmonary embolism. These events occur rarely.

• An increased risk of venous thromboembolic disease (VTE) associated with the use of oral contraceptives is well established. The excess risk of VTE is highest during the first year a woman ever uses a combined oral contraceptive. It is smaller than the risk associated with pregnancy, which has been estimated at 60 cases per 100,000 pregnancies. Venous thromboembolism is fatal in 1-2% of cases. Some epidemiological studies have reported a greater risk of VTE for women using combined oral contraceptives containing desogestrel or gestodene (the so-called third generation pills) than for women using pills containing levonorgestrel (the so-called second generation pills).

• The spontaneous incidence of VTE in healthy non-pregnant women (not taking any oral contraceptive) is about 5 cases per 100,000 women per year. The incidence in users of second generation pills is about 15 cases per 100,000 women per year. The incidence in users of third generation pills is about 25 cases per 100,000 women per year of use: this excess incidence has not been satisfactorily explained by bias or confounding. The level of all these risks of VTE increases with age and is likely to be further increased in women with other known risk factors for VTE such as obesity.

• Thrombosis has very rarely been reported to occur in other veins or arteries, e.g. hepatic, mesenteric, renal, cerebral or retinal, in COC users. There is no consensus as to whether the occurrence of these events is associated with the use of COCs.

• The risk of venous thromboembolism VTE increases with:

- increasing age;

- a positive family history (i.e. venous thromboembolism ever in a sibling or parent at a relatively early age). If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any hormonal contraceptive use;

- prolonged immobilization, major surgery, any surgery to the legs, or major trauma. In these situations it is advisable to discontinue use (in the case of elective surgery at least four weeks in advance) and not to resume until two weeks after complete remobilization;

- obesity (body mass index over 30 kg/m2);

- and possibly also with superficial thrombophlebitis and varicose veins. There is no consensus about the possible role of these conditions in the etiology of venous thrombosis.

• The use of COCs in general has been associated with an increased risk of acute myocardial infarction (AMI) or stroke, a risk that is strongly influenced by the presence of other risk factors (e.g. smoking, high blood pressure, and age) (see also below). These events occur rarely. It has not been studied how Marvelon modifies the risk of AMI.

• The risk of arterial thromboembolic complications increases with:

- increasing age;

- smoking (with heavier smoking and increasing age the risk further increases, especially in women over 35 years of age);

- dyslipoproteinemia;

- obesity (body mass index over 30 kg/m2);

- hypertension;

- migraine;

- valvular heart disease;

- atrial fibrillation;

- a positive family history (arterial thrombosis ever in a sibling or parent at a relatively early age). If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any hormonal contraceptive use.

• The increased risk of thromboembolism in the puerperium must be considered.

• Other medical conditions which have been associated with adverse circulatory events include diabetes mellitus, systemic lupus erythematosus, haemolytic uraemic syndrome, chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis) and sickle cell disease.

• An increase in frequency or severity of migraine during COC use (which may be prodromal of a cerebrovascular event) may be a reason for immediate discontinuation of the COC.

• Biochemical factors that may be indicative of hereditary or acquired predisposition for venous or arterial thrombosis include Activated Protein C (APC) resistance, hyper homocysteinaemia, antithrombin-III deficiency, protein C deficiency, protein S deficiency, antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant).

When considering risk/benefit the physician should take into account that adequate treatment of a condition may reduce the associated risk of thrombosis and that the risk associated with pregnancy is higher than that associated with COC use.

Signs and symptoms of a thrombotic event may include:

- unilateral leg pain and/ or swelling;

- sudden severe pain in the chest, whether or not reaching to the left arm;

- sudden breathlessness;

- sudden onset of coughing

- any unusual severe, prolonged headache, especially if it occurs for the first time or gets progressively worse, or is associated with any of the following symptoms:

- sudden partial or complete loss of vision or diplopia

- slurred speech or aphasia

- vertigo

- collapse with or without focal epilepsy

- weakness or very marked numbness suddenly affecting one side or one part of the body

- motor disturbances

- 'acute' abdomen

2. Tumours

• An increased risk of cervical cancer in long term users of combined oral contraceptives has been reported in some studies, but there continues to be controversy about the extent to which this is attributable to the confounding effects of sexual behaviour and other factors such as human papilloma virus (HPV).

• A meta-analysis from 54 epidemiological studies reported that there is a slightly increased relative risk (RR = 1.24) of having breast cancer diagnosed in women who are currently using combined oral contraceptives (COCs). The observed pattern of increased risk may be due to an earlier diagnosis of breast cancer in COC users, the biological effects of COCs or a combination of both. The additional breast cancers diagnosed in current users of COCs or in women who have used COCs in the last ten years are more likely to be localised to the breast than those in women who never used COCs.

• Breast cancer is rare among women under 40 years of age whether or not they take COCs. Whilst this background risk increases with age, the excess number of breast cancer diagnoses in current and recent COC users is small in relation to the overall risk of breast cancer (see bar chart).

• The most important risk factor for breast cancer in COC users is the age women discontinue the COC; the older the age at stopping, the more breast cancers are diagnosed. Duration of use is less important and the excess risk gradually disappears during the course of the 10 years after stopping COC use such that by 10 years there appears to be no excess.

• The possible increase in risk of breast cancer should be discussed with the user and weighed against the benefits of COCs taking into account the evidence that they offer substantial protection against the risk of developing certain other cancers (e.g. ovarian and endometrial cancer).

• In rare cases, benign liver tumours, and even more rarely, malignant liver tumours have been reported in users of COCs. In isolated cases, these tumours have led to life-threatening intra-abdominal haemorrhages. A hepatic tumour should be considered in the differential diagnosis when upper abdominal pain, enlarged liver or signs of intra-abdominal haemorrhage occur in women taking COCs.

3. Other conditions

• Women with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs.

• Although small increases in blood pressure have been reported in many women taking COCs, clinically relevant increases are rare. However, if a sustained clinically significant hypertension develops during the use of a COC then it is prudent for the physician to withdraw the COC and treat the hypertension. Where considered appropriate, COC use may be resumed if normotensive values can be achieved with antihypertensive therapy.

• The following conditions have been reported to occur or deteriorate with both pregnancy and COC use: jaundice and/or pruritus related to cholestasis; gallstone formation; porphyria; systemic lupus erythematosus; herpes gestationis; otosclerosis-related hearing loss; hereditary angioedema.

• Although COCs may have an effect on peripheral insulin resistance and glucose tolerance, there is no evidence for a need to alter the therapeutic regimen in diabetics using COCs. However, diabetic women should be carefully observed while taking COCs.

• Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation whilst taking this preparation.

• Marvelon contains < 80 mg lactose per tablet. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take medicine.

4.4.2 Reduced Efficacy

The efficacy of COCs may be reduced in the event of missed tablets (Section 4.2.3), gastrointestinal disturbances (Section 4.2.4) or concomitant medication (Section 4.5.1).

4.4.2 Reduced Cycle Control/ irregular bleeding

With all COCs, irregular bleeding (spotting or breakthrough bleeding) may occur, especially during the first months of use. Therefore, the evaluation of any irregular bleeding is only meaningful after an adaptation interval of about three cycles.

If bleeding irregularities persist or occur after previously regular cycles, then non- hormonal causes should be considered and adequate diagnostic measures are indicated to exclude malignancy or pregnancy. These may include curettage.

In some women withdrawal bleeding may not occur during the tablet-free interval. If the COC has been taken according to the directions described in Section 4.2, it is unlikely that the woman is pregnant. However, if the COC has not been taken according to these directions prior to the first missed withdrawal bleed or if two withdrawal bleeds are missed, pregnancy must be ruled out before COC use is continued.

4.5 Interaction with other medicinal products and other forms of interaction

4.5.1 Interactions

Interactions between oral contraceptives and other drugs may lead to breakthrough bleeding and/or contraceptive failure. The following interactions have been reported:

Hepatic metabolism:

Interactions can occur with drugs that induce microsomal enzymes, which can result in increased clearance of sex hormones (e.g., phenytoin, barbiturates, primidone, carbamazepine, rifampicin, and possibly also oxcarbazepine, topiramate, felbamate, ritonavir, griseofulvin and products containing St. John's wort).

Interference with Enterohepatic Circulation:

Some clinical reports suggest that enterohepatic circulation of estrogens may decrease when certain antibiotic agents are given, which may reduce ethinylestradiol concentrations (e.g., penicillins, tetracyclines).

Women on treatment with any of these drugs should temporarily use a barrier method in addition to the COC or choose another method of contraception. With microsomal enzyme-inducing drugs, the barrier method should be used during the time of concomitant drug administration and for 28 days after their discontinuation. Women on treatment with antibiotics (except rifampicin and griseofulvin) should use the barrier method until 7 days after discontinuation. If the period during which the barrier method is used runs beyond the end of the tablets in the COC pack, the next COC pack should be started without the usual tablet-free interval.

Oral contraceptives may interfere with the metabolism of other drugs. Accordingly, plasma and tissue concentrations may be increased (e.g., ciclosporin) or decreased (e.g., lamotrigine).

Note: The prescribing information of concomitant medications should be consulted to identify potential interactions.

4.5.2 Laboratory Tests

The use of contraceptive steroids may influence the results of certain laboratory tests, including biochemical parameters of liver, thyroid, adrenal and renal function, plasma levels of (carrier) proteins, e.g. corticosteroid binding globulin and lipid/lipoprotein fractions, parameters of carbohydrate metabolism and parameters of coagulation and fibrinolysis. Changes generally remain within the normal laboratory range.

4.6 Pregnancy and lactation

Combined oral contraceptives are not indicated for use during pregnancy. If pregnancy occurs during treatment with Marvelon, further intake should be stopped.

However, epidemiological studies have revealed no teratogenic effects when COCs were taken inadvertently during early pregnancy.

Lactation may be influenced by COCs as they may reduce the quantity and change the composition of breast milk. Therefore, the use of COCs should generally not be recommended until the nursing mother has weaned her child. Small amounts of the contraceptive steroids and/or their metabolites may be excreted with the milk but there is no evidence that this adversely affects infant health.

4.7 Effects on ability to drive and use machines

No observed effects

4.8 Undesirable effects

* Side effects marked with an asterisk have been discussed in more detail in Section 4.4.1

WHO system organ class

Common (> 1/100)

Rare (< 1/1000)

Body as a whole – general Disorders

Fluid retention

Hypersensitivity reaction

Systemic lupus Erythematosus

Cardiovascular disorders (general)

Increase in blood pressure*


Central Nervous System



Changes in libido

Depressive moods

Sydenham's chorea

Gastro-intestinal disorders




Crohn's disease

Ulcerative colitis

Hearing and vestibular disorders


Otosclerosis-related hearing loss

Liver and biliary system disorders



Cholestatic jaundice

Metabolic and nutritional disorders

Change in body weight

reduced glucose tolerance*




Breast cancer*

Cervical cancer*

Liver tumours (benign)*

Liver tumours (malignant)*

Platelet, bleeding and clotting disorders


Venous thromboembolic disorders*

Arterial thromboembolic disorders*

Reproductive disorders female

Irregular vaginal bleeding*

Breast tenderness

Breast pain

Breast secretion

Changes in vaginal secretion


Skin and appendages disorders

rash, erythema nodosum.


Herpes gestationis

Vision disorders

Contact lens intolerance


4.9 Overdose

There have been no reports of serious deleterious effects from overdose. Symptoms that may occur in this case are: nausea, vomiting and slight vaginal bleeding. There are no antidotes and further treatment should be symptomatic.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Marvelon is an oral contraceptive combination containing 150 micrograms desogestrel and 30 micrograms ethinylestradiol.

Ethinylestradiol is a well known synthetic estrogen.

Desogestrel is a synthetic progestogen. After oral administration it has a strong ovulation-inhibiting activity, a strong progestational and anti-estrogenic activity, no estrogenic activity, very weak androgenic/anabolic activity.

Paediatric population

No clinical data on efficacy and safety are available in adolescents below 18 years.

5.2 Pharmacokinetic properties



Orally administered desogestrel is rapidly and completely absorbed and converted to etonogestrel. Following ingestion of a single dose, peak serum concentrations of about 2 ng/mL are reached within 1-2 hours. At steady-state, mean peak serum concentrations of 5 ng/mL have been observed. Bioavailability is 62 - 81 %.


Etonogestrel is bound to serum albumin and to sex hormone binding globulin (SHBG). Only 2 - 4 % of the total serum drug concentrations are present as free steroid, 40 - 70 % are specifically bound to SHBG. The ethinylestradiol-induced increase in SHBG influences the distribution over the serum proteins, causing an increase of the SHBG-bound fraction and a decrease of the albumin-bound fraction. The apparent volume of distribution of desogestrel is 1.5 l/kg.


Etonogestrel is completely metabolized by the known pathways of steroid metabolism, including cytochrome P450 3A4. The metabolic clearance rate from serum is about 2 ml/min/kg. No interaction was found with the co-administered ethinylestradiol.


Etonogestrel serum levels decrease in two phases. The terminal disposition phase is characterized by a half-life of approximately 30 hours. Desogestrel and its metabolites are excreted at a urinary to biliary ratio of about 6:4.


Etonogestrel pharmacokinetics are influenced by SHBG levels, which are increased threefold by ethinylestradiol. Following daily ingestion, drug serum levels increase about two- to threefold, reaching steady state conditions during the second half of a treatment cycle.



Orally administered ethinylestradiol is rapidly and completely absorbed. Following ingestion of a single dose, peak serum concentrations of about 80 pg/mL are reached within 1-2 hours. At steady-state, mean peak serum concentrations of 130 pg/mL have been observed. Absolute bioavailability as a result of presystemic conjugation and first-pass metabolism is approximately 60%.


Ethinylestradiol is highly but non-specifically bound to serum albumin (approximately 98.5%) and induces an increase in the serum concentrations of SHBG. An apparent volume of distribution of about 5 l/kg was determined.


Ethinylestradiol is subject to presystemic conjugation in both small bowel mucosa and the liver. Ethinylestradiol is primarily metabolized by aromatic hydroxylation but a wide variety of hydroxylated and methylated metabolites are formed, and these are present as free metabolites and as conjugates with glucuronides and sulfate. The metabolic clearance rate is about 5 ml/min/kg.


Ethinylestradiol serum levels decrease in two phases, the terminal disposition phase is characterized by a half-life of approximately 24 hours. Unchanged drug is not excreted, ethinylestradiol metabolites are excreted at a urinary to biliary ratio of 4:6. The half-life of metabolite excretion is about 1 day.


Steady state concentrations are reached after 3-4 days when serum drug levels are higher by 30 - 40% as compared to single dose.

5.3 Preclinical safety data

Preclinical studies on ethinylestradiol and desogestrel revealed no special hazard for humans based on conventional studies of repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction.

However, it must be borne in mind that sex steroids can promote the growth of certain hormone-dependent tissues and tumours.

6. Pharmaceutical particulars
6.1 List of excipients


Potato starch


Stearic acid



6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years

6.4 Special precautions for storage

Do not store above 25°C. Store blisters in the original pouches.

6.5 Nature and contents of container

Push-through packs of 21 white tablets each. Tablets are round, biconvex and 6mm in diameter. They are coded on one side TR5 and on the reverse side Organon*. The pack is PVC/Al blister consisting of aluminium foil with a heat-seal coating and a PVC film. Each blister is packed in a printed aluminium pouch. The pouch is packed in a printed cardboard box together with the package leaflet (1, 3, or 50 pouches per box). (Not all pack sizes may be marketed).

6.6 Special precautions for disposal and other handling

See Section 4.2.

7. Marketing authorisation holder

Merck Sharp & Dohme Limited

Hertford Road



EN11 9BU


8. Marketing authorisation number(s)

PL 00025/0596

9. Date of first authorisation/renewal of the authorisation

04 November 1981 / 16 March 2009

10. Date of revision of the text

28 October 2013

11 Legal category

Prescription Only Medicine


Company contact details

Merck Sharp & Dohme Limited

Company image

Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU


+44 (0)1992 479 292

Stock Availability

Call MSD customer services on 01992 452094


+44 (0)1992 467 272

Medical Information e-mail

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

desogestrel, ethinylestradiol

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue